%0 Journal Article
%T Profile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma
%A Walsh GM
%J Biologics: Targets and Therapy
%D 2013
%I Dove Medical Press
%R http://dx.doi.org/10.2147/BTT.S30133
%X ofile of reslizumab in eosinophilic disease and its potential in the treatment of poorly controlled eosinophilic asthma Review (1097) Total Article Views Authors: Walsh GM Published Date January 2013 Volume 2013:7 Pages 7 - 11 DOI: http://dx.doi.org/10.2147/BTT.S30133 Received: 23 November 2012 Accepted: 14 December 2012 Published: 09 January 2013 Garry M Walsh Division of Applied Medicine, School of Medicine and Dentistry, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK Abstract: Eosinophils are important proinflammatory cells that make a major contribution to the inflammation seen in allergic diseases including asthma. Interleukin-5 is central to eosinophil maturation, release from the bone marrow, and subsequent accumulation, activation, and persistence in the tissues. Reslizumab (Cinquil ) is a humanized monoclonal antibody with potent interleukin-5 neutralizing effects, which represents a potential treatment for poorly controlled eosinophilic asthma. This review will consider the current status of the clinical development of reslizumab for asthma and in other inflammatory diseases with a marked eosinophilic component.
%K IL-5
%K asthma
%K eosinophil
%U https://www.dovepress.com/profile-of-reslizumab-in-eosinophilic-disease-and-its-potential-in-the-peer-reviewed-article-BTT